Department of Internal Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea.
Oncology. 2011;81(3-4):184-91. doi: 10.1159/000333827. Epub 2011 Nov 8.
We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection.
Between January 2006 and December 2008, 31 HCC patients received four cycles of adjuvant HAIC with 5-FU and cisplatin via port system after curative resection. During the same period, 62 patients, who did not take any adjuvant therapy, were selected as controls.
Tumor characteristics, such as distribution of TNM stage, pathologic differentiation, portal vein invasion, or microscopic invasion did not differ between control and adjuvant groups. During follow-up, recurrence developed in 11 adjuvant (35.5%) and 24 control patients (38.7%; p = 0.823). Tumor progression after recurrence was the cause of death in 2 adjuvant (28.6%) and 7 control patients (38.8%; p = 0.912). The 2-year recurrence rate was 9.1% in the adjuvant group and 4.2% in the control group, with the median recurrence-free survival time being 10.5 and 7.5 months, respectively (p = 0.324). The 3-year cumulative survival rate was 73.3% in the adjuvant group and 68.3% in the control group (p = 0.355).
Adjuvant HAIC with 5-FU and cisplatin did not offer any beneficial effect on the recurrence after curative resection of HCC.
本研究旨在探讨氟尿嘧啶（5-FU）和顺铂肝动脉灌注化疗（HAIC）辅助治疗能否降低肝癌根治性切除术后肿瘤复发。
2006 年 1 月至 2008 年 12 月，31 例 HCC 患者在根治性切除术后采用经端口系统的 5-FU 和顺铂辅助 4 周期 HAIC。同期，62 例未接受任何辅助治疗的患者被选为对照组。
两组患者在 TNM 分期、病理分级、门静脉侵犯、镜下侵犯等肿瘤特征方面无显著差异。随访期间，辅助组中有 11 例（35.5%）和对照组中有 24 例（38.7%）出现肿瘤复发（p = 0.823）。肿瘤复发后进展是导致 2 例辅助组（28.6%）和 7 例对照组患者（38.8%）死亡的原因（p = 0.912）。辅助组的 2 年复发率为 9.1%，对照组为 4.2%，中位无复发生存时间分别为 10.5 个月和 7.5 个月（p = 0.324）。辅助组的 3 年累积生存率为 73.3%，对照组为 68.3%（p = 0.355）。
氟尿嘧啶和顺铂辅助 HAIC 对肝癌根治性切除术后的肿瘤复发没有益处。
